Document Detail


ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD.
MedLine Citation:
PMID:  21356232     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Individuals with ADHD may self-medicate with nicotine, the main psychoactive ingredient in tobacco smoke, in order to reduce symptoms and negative moods associated with ADHD. ADHD medication (e.g., methylphenidate and atomoxetine) may mimic some of the effects of nicotine and may aid smoking cessation in smokers with ADHD. The present study examined if ADHD medication reduces smoking and withdrawal in non-treatment seeking smokers with ADHD. Fifteen adult smokers with ADHD participated in the study, which consisted of an experimental phase and field monitoring phase to examine the acute and extended effects, respectively, of ADHD medication. During the experimental phase, smokers were asked to complete a Continuous Performance Task (CPT) and the Shiffman-Jarvik smoking withdrawal questionnaire during the following four conditions: (1) ADHD medication+cigarette smoking, (2) ADHD medication+overnight abstinence, (3) placebo+cigarette smoking, and (4) placebo+overnight abstinence. During the field monitoring phase, participants were asked to provide salivary cotinine samples and complete electronic diaries about smoking, smoking urge, ADHD symptoms, and stress in everyday life for two days on ADHD medication and for two days on placebo. Results of the experimental phase showed that ADHD medication improved task performance on the CPT and reduced withdrawal during overnight abstinence. During the field monitoring phase, ADHD medication reduced salivary cotinine levels compared to placebo. In addition, the electronic diary revealed that ADHD medication improved difficulty concentrating during no smoking events and stress. The findings of the present study suggest that, along with other strategies, ADHD medication may be used to aid smoking withdrawal and cessation in smokers with ADHD.
Authors:
Jean-G Gehricke; Nuong Hong; Timothy L Wigal; Vivien Chan; Ashley Doan
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-02-26
Journal Detail:
Title:  Pharmacology, biochemistry, and behavior     Volume:  98     ISSN:  1873-5177     ISO Abbreviation:  Pharmacol. Biochem. Behav.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-03-28     Completed Date:  2011-07-28     Revised Date:  2012-05-02    
Medline Journal Info:
Nlm Unique ID:  0367050     Medline TA:  Pharmacol Biochem Behav     Country:  United States    
Other Details:
Languages:  eng     Pagination:  485-91     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Affiliation:
Department of Pediatrics, University of California, Irvine, CA 92612, USA. jgehrick@uci.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Attention Deficit Disorder with Hyperactivity / drug therapy*
Cotinine / blood*
Female
Humans
Male
Placebos
Substance Withdrawal Syndrome*
Grant Support
ID/Acronym/Agency:
DA018752/DA/NIDA NIH HHS; R03 DA018752-01A2/DA/NIDA NIH HHS; R03 DA018752-02/DA/NIDA NIH HHS; RR00827/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Placebos; 486-56-6/Cotinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of removing food on maintenance of drinking initiated by pairings of sipper and food.
Next Document:  Immunopharmacotherapeutic manifolds and modulation of cocaine overdose.